Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10440683 | 0.80 | DAO (0.51) | PDE10A | |
| Quinoline SCHEMBL27483163 | 0.77 | ALDH1A1 (0.52) | — | |
| SCHEMBL6933468 | 0.76 | PDGFRB (0.53) | PDE10ACYP1A2PDGFRBPDGFRAKDM1A | |
| SCHEMBL3396692 | 0.74 | CYP1A2 (0.55) | PDE10ACYP1A2PDGFRBPDGFRAKDM1A | |
| Dimethylamine SCHEMBL7748841 | 0.73 | PDE10A (0.52) | PDE10ACYP1A2PDGFRBPDGFRAKDM1A | |
| SCHEMBL10673413 | 0.73 | CYP1A2 (0.50) | PDE10ACYP1A2PDGFRBPDGFRAKDM1A | |
| SCHEMBL1772519 | 0.71 | BIRC5 (0.47) | PDE10ACYP1A2PDGFRBPDGFRAKDM1A | |
| SCHEMBL30644247 | 0.71 | CYP1A2 (0.58) | PDE10ACYP1A2PDGFRBPDGFRA | |
| SCHEMBL701411 | 0.71 | ALDH1A1 (0.53) | PDE10ACYP1A2PDGFRBPDGFRAKDM1A | |
| SCHEMBL5700742 | 0.71 | CYP1A2 (0.52) | PDE10ACYP1A2PDGFRBPDGFRAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
| EP-1479384-A1 | FIBROSIS INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209939-A1 | Pyrrole derivatives | SUMITOMO PHARMACEUTICALS CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6759429-B2 | HAVING TRANSFORMING GROWTH FACTOR- BETA INHIBITORY ACTIVITY AND BEING USEFUL AS FIBROSIS INHIBITORS FOR ORGANS OR TISSUES | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2004-07-06 | — | — | US | disclosed |
| CN-1466572-A | Pyrrole derivatives | ס����ҩ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SMAD3, MMP1, SMAD2 | PDE10A 3702/4885CYP1A2 654/4885PDGFRB 35/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | PDE10A 3656/4885CYP1A2 273/4885PDGFRB 131/4885 |
| US-20040209939-A1 | Pyrrole derivatives | NCOA1, PKD1, NCOR1 | PDE10A 3654/4885CYP1A2 250/4885PDGFRB 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.